Inhibition of the Interaction of Urokinase-Type Plasminogen Activator (uPA) with Its Receptor (uPAR) by Synthetic Peptides
- 1 January 1997
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry
- Vol. 378 (3-4), 231-238
- https://doi.org/10.1515/bchm.1997.378.3-4.231
Abstract
Focusing of the serine protease urokinase-type plasminogen activator (uPA) to the cell surface via interaction with its specific receptor (uPAR, CD87) is an important step for tumor cell invasion and metastasis. The ability of a synthetic peptide derived from the uPAR-binding region of uPA (comprising amino acids 16-32 of uPA; uPA(16-32)) to inhibit binding of fluorescently labeled uPA to uPAR on human promyeloid U937 cells was assessed by quantitative flow cytofluorometric analysis (FACS) and compared to the inhibitory capacities of other synthetic peptides known to interfere with uPA/uPAR-interaction. An about 3000-fold molar excess of uPA(16-32) resulted in 50% inhibition of pro-uPA binding to cell surface-associated uPAR. Using a solid-phase uPA-ligand binding assay employing recombinant soluble uPAR coated to microtiter plates, the minimal binding region of wild-type uPA was determined. The linear peptide uPA(19-31) and its more stable disulfide-bridged cyclic form (cyclo(19,31)uPA(19-31)) displayed uPAR-binding activity whereas other peptides such as uPA(18-30), uPA(20-32) or uPA(20-30) did not react with uPAR. Cyclic peptide derivatives of cyclo(19,31)uPA(19-31) in which certain amino acids were deleted and/or replaced by other amino acids as well as uPAR-derived wild-type peptides did also not inhibit uPA/uPAR-interaction. Therefore, the present investigations identified cyclo(19,31)uPA(19-31) as a potential lead structure for the development of uPA-peptide analogues to block uPA/uPAR-interaction.Keywords
This publication has 33 references indexed in Scilit:
- Regulation of Integrin Function by the Urokinase ReceptorScience, 1996
- Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasisInternational Journal of Cancer, 1996
- Prevention of prostate‐cancer metastasis in vivo by a novel synthetic inhibitor of urokinase‐type plasminogen activator (uPA)International Journal of Cancer, 1995
- Chemical Modification of the Urokinase-Type Plasminogen Activator and Its Receptor Using Tetranitromethane. Evidence for the Involvement of Specific Tyrosine Residues in Both Molecules during Receptor-Ligand InteractionBiochemistry, 1995
- Expression of the human urokinase‐type plasminogen activator receptor in E. coli and Chinese hamster ovary cells: Purification of the recombinant proteins and generation of polyclonal antibodies in chickenElectrophoresis, 1995
- Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA)FEBS Letters, 1994
- Tumor-Associated Urokinase-Type Plasminogen Activator: Biological and Clinical SignificanceBiological Chemistry Hoppe-Seyler, 1992
- Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acidsInternational Journal of Peptide and Protein Research, 1990
- Electrospray Ionization for Mass Spectrometry of Large BiomoleculesScience, 1989
- 9-Fluorenylmethoxycarbonyl amino-protecting groupThe Journal of Organic Chemistry, 1972